Study assessments
Tumor, Cancer
ADVERSE EVENT, TUMOR, DISEASE, DISEASE, CANCER
Disease was assessed by the investigator using computed tomography scans of the chest, abdomen, pelvis and any other disease location performed with intravenous contrast. Baseline brain magnetic resonance imaging was required at screening for patients enrolled in the dose-expansion cohort. Monitoring for CNS disease was performed in accordance with local practice. Tumor response was assessed by the investigator using RECIST version 1.1. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.